Technology Offerings

R-Spondin 3 Binds Syndecan 4 to Modulate Wnt Pathway

The commercial opportunity is to develop antagonists of Rspo2 and/or Rspo3 for the treatment of Sdc(Syndecan)-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders.

Further Information: PDF

Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Comments (0)

Write a comment